Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

Learn more about:
Related Clinical Trial
Induction of Cortical Plasticity S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Comparing Immobilisation Shells in Cranial Radiotherapy FBY PET/CT in Patients With Brain Tumors Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Prevalence of Post-craniotomy Headache in Siriraj Hospital Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma Wise Cortical Strip for Intraoperative Neurophysiological Monitoring Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) A Study of Cognitive Changes in Patients Receiving Brain Radiation

Brief Title

Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

Official Title

Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

Brief Summary

      The study population was selected from high grade glioma pateints attending the Department of
      Clinical Oncology, Assiut University hospital during the period from December 2018 to
      September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression

Detailed Description

      Glioblastoma is the most common malignant primary brain tumor in adults, and despite
      aggressive treatment, it is incurable Patient prognosis differs considerably within the
      different World Health Organization (WHO) grades, poorest prognosis for patients with the
      grade IV tumour- the glioblastoma multiform (GBM).

      Fibrinogen-like protein 2 (FGL2),regulates both innate and adaptive immunity. FGL2 is a 439
      amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen.

      Secreted FGL2 (sFGL2) is the key regulator in immunosuppression may play important role in
      malignant transformation of low to high by inhibiting the proliferation of T cell Study the
      role of fibrinogen-like protein2 on Immunosuppression and progression ,free survival and
      overall survival in high grade glioma

Study Type


Primary Outcome

Rple of FGL2in high grade glioma as aprognostic factor


Brain Tumor Adult


FGL2 immunohisyochemistry


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 1, 2019

Completion Date

September 1, 2021

Primary Completion Date

September 1, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Pateints>18 years old

          -  Pathologically proven high grade glioma

          -  Total or subtotal resection of the tumor

          -  Patients received concurrent radiation therapy with temozolomide followed by adjuvant
             temozolamide for 6 months

        Exclusion Criteria:

          -  Pregnancy

          -  Breast feeding

          -  Other comorbidity

          -  Previous malignancy or radiation therapy or chemotherapy




18 Years - 85 Years


, 01222302375, [email protected]

Administrative Informations



Organization ID

FGL2 in brain cancer

Responsible Party


Study Sponsor

sohaila Essam

Study Sponsor

, , 

Verification Date

October 2019